The Chinese regulator NMPA has approved the drug Esundexian (Sunharbo) from the German company Bayer for the prevention of recurrent strokes in elderly patients, Kommersant writes. The drug became the world's first registered inhibitor of blood clotting factor XIa. According to the results of international studies that included more than 12,300 people, adding the drug to the standard treatment reduced the risk of ischemic stroke by 26% compared to the use of antiplatelet drugs alone.

The Chinese regulator NMPA has approved the drug Esundexian (Sunharbo) from the German company Bayer for the prevention of recurrent strokes in elderly patients, Kommersant writes. The drug became the world's first registered inhibitor of blood clotting factor XIa. According to the results of international studies that included more than 12,300 people, adding the drug to the standard treatment reduced the risk of ischemic stroke by 26% compared to the use of antiplatelet drugs alone.